T he expression of HLA class II molecules is essential for Ag-specific immune responses and is very tightly regulated at the transcriptional level. The impairment of both constitutive and IFN-␥-induced HLA class II gene expression is characteristic of MHC class II immunodeficiency, an autosomal recessive disorder. It results from the defective transcription of all MHC class II genes (1, 2) . Since this disease was first described, ϳ70 patients, in 50 families, have been reported. Four major complementation groups (A, B, C, and D) have been described by analyzing B cell lines from patients and experimental mutant HLA-deficient cell lines (3) (4) (5) . The genes responsible for this deficiency encode the proteins that coordinately control MHC class II locus expression; these are class II trans-activator (CIITA), 3 regulatory factor binding to the X box (RFX) protein containing ankyrin repeats, RFX5, and RFXassociated protein (6 -9) .
In a clinical survey of 30 patients, MHC class II deficiency resulted in combined T and B cell immunodeficiency, with an early onset and an average life expectancy of 4 years (10) . Bone marrow transplantation was proposed as the only curative treatment (11) due to the very poor prognosis of most patients (despite appropriate medical care).
We report herein an unusual MHC class II deficiency phenotype in three affected siblings. Two siblings, now 21 and 22 years old, are mildly affected, and the third, who is 24 years old, is asymptomatic. However, apart from residual HLA-D staining in PBMC and rare HLA-DR-positive dermal macrophages, HLA class II expression was not detected in these siblings. Consistent with the biological manifestations, but not the clinical status of the patients, a mutation in CIITA gene was detected, which is responsible for the defect in bare lymphocyte syndrome (BLS) complementation group A. This homozygous L469P substitution in the coding region of the CIITA cDNA was shown to be responsible for defective expression of MHC-II.
B cell lines and SV40-transformed skin fibroblasts were obtained and cultured as described previously (4) . Fibroblasts, or their heterokaryons, were treated by IFN-␥ (Genex, 250 and 500 IU/ml) for 48 h before analyzing MHC class II expression. DLD1 is a gut epithelial cell line, which was donated by Dr. N. Cerf-Bensussan. RJ 2.5.5 is a CIITA-deficient variant of the Raji cell line. ABL, SJO, and ZM are EBV-transformed cell lines from MHC-II-deficient patients from the B, C, and D complementation groups, respectively (5). The RC SV40-transformed fibroblast cell line was established from another CIITA-deficient patient (4).
Immunofluorescence
The anti-HLA Abs used were anti-class HLA II (-DR, -DQ, -DP) clone IQU9 (BioDesign, Carmel, NY), and the anti-class I Ab was W6/32 (SeraLab, Crowley, U.K.). The HLA-II isotype-specific mAbs were: anti-DR L243 IgG2a (BD Biosciences, San Jose, CA) or L112, anti-DP L227; anti-DQ Genox or L2. The anti-CIITA Abs were IgG1 clone 7-1H (R&D Systems, Minneapolis, MN). Ab binding was revealed by incubation with an anti-mouse Ig coupled to FITC (Immunotech, Luminy, France). Anti-DR L243 mAb, directly coupled to FITC (BD Biosciences) was also used. Anti-CD4, -CD8, -CD14, -CD19, and -CD25 have been described elsewhere (12) . PBMC, B cells, untreated and IFN-␥-induced fibroblasts, and different stable transfectants were stained in suspension and analyzed with a BD Biosciences cytofluorograph. Fibroblasts transfected with pEGFP vectors were fixed after transfection with 0.1% glutaraldehyde for 48 h and 2% formaldehyde in PBS for 5 min, permeabilized with cold (Ϫ20°C) 100% methanol for 5 min, stained with 4Ј,6Ј-diamidino-2-phenylindole and analyzed with a Leitz Ortoplan microscope.
Somatic complementation analysis
B and fibroblasts cell lines from the patients and the RJ 2.5.5, ABL, SJO, and ZM B cell lines, previously classified into complementation groups A, B, C, and D, respectively, and fibroblasts RC (group A) and ZM (group D) were used to obtain transient heterokaryons, as previously described (4) . KER B cell lines (13, 14) from the patients were also used. Phenotypic complementation was tested by immunofluorescence 48 -72 h after cell fusion. Fibroblasts were treated with IFN-␥ for 48 h before immunofluorescence analysis.
Nucleic acid analysis
RNA extraction and RT-PCR analysis were conducted as previously described (4, 5) . The CIITA was sequenced according to standard methods. PCR products were purified with the Aquick Kit (Qiagen, Chatsworth, CA). The DNA sequence of both strands was determined by Taq polymerase cycle sequencing with fluorochrome-labeled dideoxy terminators and resolved by a laser detection system (310 ABI sequencer; Applied Biosystems, Foster City, CA).
Mutagenesis
Mutagenesis of pIRES-and pEGFP-WT-CIITA vectors was conducted by use of the Transformer Site-Directed Mutagenesis kit (Clontech Laboratories, Palo Alto, CA), according to the manufacturer's instructions. The primers used were: F, 5Ј-CAG GAT CTG CCC TTC TCC CTG-3Ј; and R, 5Ј-CAG GGA GAA GGG CAG ATC CTG-3Ј. The pIRES-and pEGFP-CIITA-L469P clones were sequenced before the transfection experiments.
Transfections
Transfection experiments with wild-type (WT) and mutated CIITA vectors were conducted as previously described (5) . The plasmids used were pIRES-WT-CIITA, pIRES-L469P-CIITA, pEGFP-WT-CIITA, pEGFP-L469P-CIITA, pEGFP-CIITA-MT1 (15) and the corresponding empty vectors, pIRES-neo and pEGFP (both from Clontech). EGFP-CIITA is an N-terminal fusion of EGFP to the second in-frame ATG of the gene encoding CIITA. Stable pIRES-WT-CIITA and -L469P-CIITA transfectants were analyzed 2-6 wk after transfection.
CIITA protein sequence homologies
Sequences homologous to CIITA were identified through BLASTp and tBLASTN (16) 
Results

Clinical and immunological investigations
MHC class II deficiency was detected in siblings SaE, SaM, and SaA at 15, 12, and 11 years of age, respectively. The patients are of Greek origin and were born to nonconsanguinous parents. Immunodeficiency was diagnosed in SaM and SaA (Tables I and II) and clinical and biological findings were consistent throughout the 7-year follow-up period. The immune status of SaE was tested because of her sisters' disease, but she never underwent treatment. In addition to the HLA-D expression defect, the siblings had hypoglobulinemia and an absence of Ag-induced in vivo and in vitro immune responses after immunization. Serum Abs to common germs (Streptococcus pneumoniae and Haemophilus influenzae) were detected in SaE. A minor CD4 lymphopenia was detected in SaA ,whereas her sisters had normal CD4 T cell counts. Patients SaM and SaA were treated symptomatically, and a prophylactic treatment with intravenous Ig was then started and has been continued since for sibling SaM. SaM became asymptomatic and has remained so for the last 3 years, as is the eldest sibling, SaE, without treatment. Currently, both SaM and SaE refuse to be followed by the immunology department. No information is available on the follow-up of SaA.
Membrane expression of HLA-DR, -DQ, and -DP molecules in family Sa and in other MHC-II-deficient patients
Defective expression of HLA-DR, -DQ, and -DP molecules was observed by immunofluorescence analysis in all three patients ( Fig. 1 and data not shown). In resting PBMC (Fig. 1a) , B cells (CD19 panels) and monocytes (CD14 panels) were faintly stained with anti-HLA-DR mAbs L243 and L112. HLA-DQ was weakly expressed on B cells and monocytes, and HLA-DP was faintly detected on monocytes (Fig. 1a) . PHA-induced T cell blasts were HLA-DR, -DQ, and -DP negative (Fig. 1b) , as were CD4 and CD8 MLR-induced blasts (Fig. 1c) . In contrast, PHA and MLR blasts expressed CD25 normally (shown for MLR blasts (Fig. 1c) ). EBV B cell lines from SaE and SaM did not express HLA-DR, -DP, or -DQ (Fig. 1d) , although FACS staining revealed low, but detectable, levels of HLA-DQ and -DP expression on fresh B CD19 cells.
In another BLS patient, HeJ (BLS complementation group A) with a severe clinical phenotype, the residual HLA-DR expression observed for Sa siblings was not detected on CD19 ϩ B cells with either anti-HLA-DR Abs (Fig. 1e, DR1 and DR2 ). In contrast, monocytes of one 14-year-old RFX protein containing ankyrin repeats-deficient patient, KhM, displayed a similar residual expression of HLA-DQ and -DP on CD14 ϩ cells (Fig. 2f) . Interestingly, patient KhM also suffered from a milder form of immunodeficiency.
Skin biopsies from SaM and SaE (Fig. 2 , D and E) were studied for HLA-DR expression (left) of dendritic cells identified by antiCD1a staining (middle) and macrophages, identified by anti-CD68 staining (right), and compared with control skin (top). HLA-DR expression was not detected on patients' CD1a-postive epidermal dendritic cells (Fig. 2, D and G) in contrast to control dendritic cells ( Fig. 2A) . However, several HLA-DR-positive dermal macrophages were detected in patients (Fig. 2, D and G) , albeit in lower numbers than in control biopsies. (Fig. 2A) . Similar findings, i.e., HLA-DR expression of dermal macrophages, were observed in skin of two other patients ages 21 and 14 years, both with a mild clinical presentation and belonging to complementation group B (C. Picard, W. Wiszniewski, M. C. Fondaneche, V. Pinet, F. Le Deist, S. Blanche, J. F. Eliaou, J. L. Casanova, A. Fischer, and B. Lisowska-Grospierre, unpublished observations).
Classification of HLA class II deficiency in complementation group A in the Sa family
B cell somatic fusions induced the expression of HLA-class II in heterokaryons between ABL, SJO, and ZM cells, belonging to the complementation groups B, C, and D, respectively, in SaE. Heterokaryons between SaE and RC fibroblasts from group A were HLA class II negative. Somatic complementation was also obtained between B cells from SaE and patient KER (14), who did not belong to the A-D complementation groups. Correction of the HLA-II expression was obtained by transfection of SaE and RC fibroblasts with the CIITA cDNA (see below).
CIITA mutation
The CIITA mRNA from EBV cell lines from Sa patients was amplified by RT-PCR and analyzed by sequencing. A single homozygous T1524C mutation, causing a leucine to proline substitution at position 469 (L469P), was found in all three patients. This mutation was confirmed in the genomic level (Fig. 3) . A heterozygous mutation was found in the mother. No cells were available from the father. No other mutations were found in the entire 4.5-kb CIITA cDNA.
Functionional analysis of the L469P CIITA
The CIITA-negative epithelial cell lines DLD1 and HeLa, the CIITA-deficient Burkitt lymphoma cell line RJ2.2.5, and the fibroblast cell line RC were stably transfected with the expression vector pIRES containing WT-CIITA or L469P-CIITA and tested for HLA-DR expression. Sixty percent of the DLD1 and HeLa cells transfected with WT-CIITA expressed HLA-DR (Fig. 4 b and  e) , whereas only 0.5% of cells transfected with the empty vector were DR ϩ (Fig. 4, a and d) . From 1 to 4% of the DLD1 and HeLa L469P-CIITA transfectants were DR ϩ cells (Fig. 4, c and f) . Of the RJ2.2.5 cells transfected with the same vectors, 80% of the WT transfectants became HLA-DR ϩ (Fig. 4h) , whereas 14% of the L468P transfectants expressed HLA-DR (Fig. 4i) . Ninety-six percent of the RC cells transfected with WT-CIITA expressed HLA-DR at a mean fluorescence intensity of 1 ϫ 10 Ϫ4 (Fig. 4k) . Thirty-one percent of cells transfected with L469P-CIITA displayed HLA-DR staining, although at a mean fluorescence intensity of between 10-and 1000-fold lower (Fig. 4l) . Western blots of total cell lysates from transfected fibroblasts were used to assess the level of transgene expression and showed that it was even higher for the L469P CIITA protein than for the WT-CIITA (not shown).
We assessed intracellular expression of L469P CIITA by transfecting the RC CIITA-deficient fibroblasts with pEGFP-WT-CIITA and pEGFP-L469P-CIITA and comparing the expression pattern with that of the experimental cytoplasmic retention mutant, MT1-CIITA (15) . A preferentially nuclear localization of CIITA was observed in both the WT-and L469P-CIITA transfectants (Fig. 5, top and middle) . An exclusively cytoplasmic CIITA staining was detected in the pEGFP-MT1-CIITA transfectants, as previously reported (Fig. 5, bottom, 
L469 is conserved in homologous CIITA proteins
L469 is part of a so-called leucine-charged domain (LCD); 465LQDLL469) conforming to the consensus LxxLL. Replacement of all theree leucines by alanine severely impaired CIITA function (23) . Recently, several sequences were discovered that contained homologies to both the nucleotide-binding domain and the C-terminal leucine-rich repeats (LRRs) of CIITA (19 -22) . To test whether the region containing L469 is conserved among these proteins, we identified CIITA-homologous sequences through Blast searches and performed multiple sequence alignments of the corresponding region with the three known CIITA sequences (human, mouse, rat) and four homologous sequences (NOD1/CARD4, NOD2, CARD7, and sequence AC008753). Fig. 6 shows the part of CIITA containing both the P loop region (positions 420 -427), the Mg 2ϩ coordination region (461DAYG464), and the LCD motif (23, 24) . Whereas the P loop region is very highly conserved among all sequences, the DxxG motif in human CIITA is only partly conserved in mice and rats and not at all in the other CIITAhomologous sequences. The LxxLL motif is also highly conserved among the different sequences with an acidic amino acid at position 3 (D/E). The most highly conserved amino acid is L468, which is invariant among all sequences. Residue L469 is also highly conserved with only two conservative exchanges of the leucine to isoleucine (Fig. 6 ).
Discussion
The MHC class II deficiency disease has been described as being lethal in childhood, with a mean survival age of 5 years, despite appropriate medical care. We describe herein three affected siblings who are still alive at 21, 22, and 24 years of age. The eldest patient suffered very few infections in early childhood and since then has been asymptomatic without any treatment. Her sisters suffered from mild immunodeficiency. None of them was prone to opportunistic infections. These patients do not suffer from the protracted diarrhea that affects most MHC II-deficient patients. Nevertheless, the main immunological manifestations of MHC class II expression defect were, with one exception, similar to those reported in other cases of MHC II deficiency, namely, IgG2 and IgA hypogammaglobulinemia and the absence of Ag-induced responses in vivo and in vitro. Unexpectedly, in contrast to most other MHC II-deficient patients who are T CD4 lymphopenic, CD4 cell counts were normal in SaE and SaA and only slightly lower in SaM. This suggests that in the three Sa patients the MHC-II expression defect has led to less severe consequences on T cell differentiation than observed in other patients.
The HLA-II molecule expression defect in the Sa siblings was found in B lymphocytes, monocytes, IFN-␥-induced fibroblasts, dendritic cells, and T and B cell blasts. However, faint but detectable HLA-DR, -DQ and -DP staining was observed on B cells and monocytes. Similarly, there was faint but detectable HLA-D staining on PBMC from KhM, another MHC-II-deficient patient from complementation group B suffering from a milder form of immunodeficiency (Fig. 1f) . In contrast, B cells from HeJ, a CIITAdeficient patient with a severe immunodeficiency, were HLA-DR Ϫ (Fig. 1e) . Therefore, it appears that a residual HLA-D staining of PBMC correlates with less severe clinical symptoms. We have no explanation why there was no residual HLA-D expression on any blast types. Although mitogen and MLR stimulation led to blastogenesis and the expression of CD25 on both CD4 and CD8 T cell blasts (shown for SaA, Fig. 1c) , in both patients Sa and HeJ T and B cell blasts were HLA-II negative (Fig. 1, b, c, and e) . However, in patients Sa, in addition to PBMC, some dermal macrophages were HLA-DR ϩ , although dermal dendritic cells were not. MHC II-deficient patients with mild clinical presentation have previously been reported, e.g., the 7-year-old KER twins. Their T cells were able to respond in vivo to antigenic challenge (13, 14) . Although the molecular basis of the MHC II defect was not elucidated in these twins, the Sa patients do not share the same defects, because their cells complemented the KER cell line for MHC-II expression.
Complementation experiments by somatic cell fusion assigned the Sa family defect to complementation group A, indicating that the CIITA gene was affected in cis. CIITA encodes a 1130-aa protein, the N-terminal region of which acts as a transcriptional activator and the C-terminal region of which provides MHC-II promoter specificity (6, 25, 26) . CIITA controls both constitutive and inducible MHC-class II expression (27) and is considered to be a master gene in MHC class II regulation. In all tissues tested, CIITA expression correlates with MHC class II expression (28, 29) , and CIITA knockout mice reproduce the phenotype of CIITAdeficient patients with only minor differences (30) .
Analysis of the CIITA gene in family Sa revealed a homozygous T1524C substitution which is responsible for a leucine to proline missense mutation at aa 469 (L469P) in the CIITA coding region.
All group A patients studied thus far have T and B immunodeficiency, with severe clinical consequences (10) . In one case, patient BCH, a stop codon was found at position 1256 in one CIITA allele. However, all other patients with a severe phenotype carry mutations in the 3Ј end of the CIITA gene (6, (31) (32) (33) (34) . This is consistent with mutation analysis, which showed that MHC class II specific transcription depends on the 830 C-terminal residues of CIITA (25, 26) .
The L469P mutation is the first CIITA mutation to be identified in the N-terminal part of this 830-aa region which contains a LCD (LCD motif) essential for CIITA activity (23) . This motif is very close to the second tripartite GTP-binding region motif, described by Harton et al. (24) . A mutant, in which the conserved LCD1 motif leucine residues (positions 465, 468, and 469) were replaced with alanines, was unable to drive transcription from the DR-X1-X2-Y or -W-X-Y promoters (23) . Recently, several sequences showing homology to the nucleotide binding and LRR regions of CIITA have been published (19 -22) . A search for protein sequence homologies revealed that the LCD motif containing L469 is very highly conserved in these sequences. Position 468 is the most conserved, but L469 is also highly conserved, indicating a functional relevance of this motif in this group of GTP-binding proteins (Fig. 6) . It also shows that other human proteins share this motif. In the CIITA gene of the Sa family, only leucine 469 was replaced (by proline), indicating the importance of this motif in vivo.
Functional analysis revealed that the L469P allele of CIITA is not completely inactive. Stable transfection of DLD1 or HeLa cells with the L469P-CIITA cDNA did not lead to the trans activation of MHC-II genes, but we observed a residual trans activation potential of L469P-CIITA in RC and in RJ2.2.5 cells (Fig. 4, i and l) . In the patient-derived, CIITA-deficient RC fibroblasts transfected with L469P-CIITA, DR expression was restored in 30% of cells, albeit at a much lower level than that observed in WT-CIITA transfectants. In the RJ2.5.5 B cell line, which has genomic deletions of the CIITA gene (6), transfection with L469P CIITA led to an abnormally low but clearly detectable HLA class II expression in 14% of the cells. The mutated CIITA alleles from patients BLS-2 (⌬940 -963) and BCH (BCH-1 ⌬1079 -1106; BCH-2 E381Stop) had been tested functionally in RJ2.2.5 earlier. None of these alleles, which were derived from patients with severe immunodeficiency, led to residual HLA class II expression in RJ2.2.5 (6, 32) . Thus, partial HLA-DR expression in the RJ2.5.5 and RC transfectants shows that the expression of the L469P-CIITA cDNA allows partial trans activation of MHC II genes. This probably corresponds to the residual MHC class II expression detected on fresh PBMC from the patients.
The immunofluorescence data suggest that the recombinant L469P-CIITA protein can translocate into the nucleus (Fig. 5) . This result is confirmed by Western blotting, which revealed the presence of full length L469P-CIITA protein in nuclear extracts (G. Barbieri, T. Prod'homme, J. Vedrenne, B. Lisowska-Grospierre, D. Charron, and C. Alcaide-Loridan, manuscript in preparation). Therefore, the L469P mutant is the first loss-of-function mutant that retains the ability to translocate into the nucleus. Interestingly, a mutation in the 461DAYG465 motif that correlates with the conversion of CIITA to the GDP-bound state leads to its exclusion from the nucleus (24) . The mutation (proline 469) is very close to the 461DAYG465 motif and it may therefore be informative to test the GTP binding of mutated CIITA, even if nuclear exclusion is not observed in transfectants. The LCD1 motif mutated in Sa CIITA conforms to the short LxxLL consensus of a putative nuclear export sequence, but the fact that the L469P mutant protein is found in the nucleus argues against such a function for this sequence. The role of neither the LCD nor the GTP-binding motif (24) or of a recently shown (35) interaction between the GTP-binding region (residues 336 -702) and the C-terminal leucine-rich region, LRR (15) , are well understood. Thus, further studies on the L469P CIITA displaying these unusual features will contribute to our understanding of the mechanisms that govern nuclear translocation and transcriptional activation of CIITA.
Although it cannot be formally proved, it is tempting to speculate that the residual HLA class II expression in cells from the Sa siblings and indeed the residual trans activation potential of the L469P allele of CIITA are responsible for the lesser severity of the immunodeficiency than that affecting other patients. Residual HLA class II expression was not observed on fresh B cells from two other CIITA-deficient patients, patient HeJ (Fig. 1e ) and patient BCH (31) . However, a milder immunodeficiency associated with a residual HLA class II expression has been described for the Ker/ Ken twins (14) and is shown here for a patient KhM from BLS group B (Fig. 1f ). An unrelated patient with MHC II deficiency caused by a CIITA defect presenting similarities with the Sa patients has been described (33) . This patient was not diagnosed until the age of 27 years, well beyond the life expectancy of most BLS patients. Clinical and immunological data for the patient have not been reported. Interestingly, a single amino acid substitution, F962S, was found in the coding region of CIITA (33) . The patients we describe are the first in which a mild phenotype of the disease can be correlated with a residual trans activation potential of the mutated regulatory factor (Fig. 4) . It can be assumed that the ensuing residual HLA class II expression in the patients is responsible for a substantial T cell differentiation and the capacity to mount CD4 T cell-dependent immune responses in vivo. The fact the patients did not develop the protracted diarrhea that affects most patients with MHC II deficiency may be a consequence of residual MHC II expression in intestinal epithelium, like that in PBMC.
These observations on MHC II deficiency in the Sa family have important medical implications. They show that an asymptomatic clinical course or an attenuated clinical phenotype can be observed in patients with a profound defect in the expression of HLA class II genes. Therefore, in patients with mild symptoms of immunodeficiency, an inherited MHC II expression defect should be considered. In CIITA-deficient patients, residual HLA-DR expression in peripheral blood leukocytes might be of prognostic value. When such residual HLA-DR expression is detected and coincides with an absence of severe infections, bone marrow transplantation should not be recommended. However, even those MHC II-deficient patients whose clinical status is good should be kept under close medical surveillance because late onset immunodeficiency can be fatal.
